Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01789827
Other study ID # MC1274
Secondary ID NCI-2013-00297Mo
Status Completed
Phase Early Phase 1
First received
Last updated
Start date March 2014
Est. completion date June 27, 2018

Study information

Verified date April 2019
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot clinical trial studies aldesleukin imaging in viewing tumor growth in patients with stage IV melanoma receiving ipilimumab or pembrolizumab therapy. Diagnostic procedures, such as single-photon emission computed tomography (SPECT), uses radioactive drugs and a scanner to make detailed pictures of areas inside the body and may be a less invasive way to check for stage IV melanoma. Radioactive drugs, such as technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2, carry radiation directly to cancer cells and may be able to differentiate between tumor growth due to inflammation versus tumor progression in patients with stage IV melanoma receiving therapy.


Description:

PRIMARY OBJECTIVES:

I. Feasibility/biodistribution of 99mTc-HYNIC-IL2 (technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin 2) scintigraphy in patients with metastatic melanoma undergoing immunotherapy with either ipilimumab (commercial source) or pembrolizumab.

SECONDARY OBJECTIVES:

I. Correlation of tumor infiltrating lymphocyte (TIL) invasion (scintigraphy/histology) with tumor burden; and description of any clinical side effects associated with imaging.

TERTIARY OBJECTIVES:

I. Correlation of TIL invasion assessed by 99mTc-HYNIC-IL2 scintigraphy vs. histology (total and subsets of TIL), as well as screen for peripheral blood correlates.

OUTLINE: Patients are assigned to 1 of 2 groups. COHORT I: Patients undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy prior to receiving ipilimumab or pembrolizumab and at 12 weeks.

COHORT II: Patients undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy prior to receiving ipilimumab or pembrolizumab, at 3-4 weeks, and at 12 weeks.

After completion of study treatment, patients are followed up at 30-45 days.


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date June 27, 2018
Est. primary completion date June 27, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Pathologic proof of stage IV melanoma (pathology report confirmation) with plans to initiate therapy with ipilimumab or pembrolizumab according to Food and Drug Administration (FDA) approved guidelines, with multiple lesions such that

- Two of these lesions are in the same organ and at least one of these two lesions is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 using either intravenous (IV) contrast enhanced computed tomography (CT) or CT component of positron emission tomography (PET)/CT OR

- Three of these lesions are in different organs and at least one of these 3 lesions is measurable by RECIST 1.1 using either IV contrast enhanced CT or CT component of PET/CT

- Patient eligible for and will be receiving ipilimumab or pembrolizumab as standard of care therapy

- Absolute neutrophil count (ANC) >= 1500 mL

- Hemoglobin (Hgb) > 10 g/dL

- Platelets (PLT) >= 50,000 mL

- Aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)

- Alkaline phosphatase =< 3 x ULN; up to 5 x allowed for patients with liver metastases

- Ability to provide informed consent

- Willingness to return to Mayo Clinic Rochester for follow-up

- Life expectancy >= 12 weeks

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2

- For women of childbearing potential, a negative serum pregnancy test =< 7 days prior to registration

- Willingness to participate in mandatory imaging studies as well as provide mandatory blood samples for correlative research

- Tumor accessible for biopsy

Exclusion Criteria:

- Uncontrolled or current infection

- Known allergy to 99mTc-HYNIC-IL2 or components

- Any of the following prior therapies with interval since most recent treatment:

- Chemotherapy =< 3 weeks prior to registration

- Biologic therapy =< 3 weeks prior to registration

- Radiation therapy =< 3 weeks prior to registration

- Failure to recover from side effects of prior chemotherapy or surgery

- Any of the following:

- Pregnant women

- Nursing women

- Women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device [IUD], surgical sterilization, subcutaneous implants, or abstinence, etc.)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Laboratory Biomarker Analysis
Correlative studies
Procedure:
Radionuclide Imaging
Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
Biological:
Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2
Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies

Locations

Country Name City State
United States Mayo Clinic Rochester Minnesota

Sponsors (2)

Lead Sponsor Collaborator
Mayo Clinic National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients who develop scintigraphy limiting toxicities (SLTs) SLTs include grade 2+ allergic reaction, grade 3+ anaphylaxis, grade 2+ injection site reaction, or grade 3+ non-hematologic toxicity (not attributed to immunotherapy treatment/progression or a co-morbid condition). A 95% binomial confidence interval of the proportion of patients who develop a grade 2+ allergic reaction, grade 3+ anaphylaxis, or grade 2+ injection site reaction will be constructed. Up to 12 weeks
Secondary Incidence of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Up to 30-45 days after study discontinuation
Secondary Target-to-background (T/B) ratio as determined by technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy Spearman rank correlation coefficients will be used to examine the association between T/B ratio and the pre-treatment tumor biomarkers. Spearman rank correlation coefficients will be used to examine the association between changes in T/B ratio, changes in TIL percentages, and changes in peripheral blood concentrations of T, B, and NK cell subsets. Up to 12 weeks
Secondary TIL invasion as determined by technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy Relationship between TIL invasion, tumor burden, tumor based biomarkers, and peripheral blood biomarkers will be assessed. Up to 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT01886235 - Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery N/A
Completed NCT01961115 - Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Phase 2
Completed NCT02858869 - Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Phase 1
Completed NCT03229278 - Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Phase 1
Completed NCT01989559 - Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery Phase 1
Withdrawn NCT02812693 - Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification Phase 1/Phase 2
Completed NCT00026221 - Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma Phase 2
Active, not recruiting NCT02876068 - Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies Phase 1
Completed NCT01131234 - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00397982 - Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma Phase 2
Terminated NCT01744171 - Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma Phase 1
Terminated NCT02748564 - Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Phase 2
Completed NCT02941744 - A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases Phase 1/Phase 2
Terminated NCT01970527 - Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma Phase 2
Active, not recruiting NCT02654821 - Study With T-cel Receptor Gene Therapy in Metastatic Melanoma Phase 1/Phase 2
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Completed NCT00866177 - MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma Phase 2
Active, not recruiting NCT03719131 - Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy Phase 2
Completed NCT02716948 - SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine Phase 1
Completed NCT00110019 - Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Phase 3